Dr. Lal Pathlabs edges ahead on strong quarterly results.
DSIJ Intelligence / 07 Aug 2017
Dr. Lal Pathlabs Ltd. reported its results for the quarter ended June 30, 2017 today. The consolidated numbers were largely strong and higher than the consensus estimates.
Dr. Lal Pathlabs Ltd. reported its results for the quarter ended June 30, 2017 today. The consolidated numbers were largely strong and higher than the consensus estimates.
The company's total sales for Q4FY17 came in at Rs 249.3 crore, which represents a 13.37 per cent sequential increase and 11.84 per cent YoY increase.
Its operating profit (EBIT) for the quarter amounted to Rs 58.7 crore and its EBIT margin stood at 23.55 per cent.
The company reported PAT of Rs 44.4 crore, which represents a sequential QoQ increase of 40.95 per cent and a YoY increase of 9.9 per cent.
Dr. Lal PathLabs Limited is engaged in providing diagnostic and related healthcare tests and services. The company is engaged in the business of running laboratories for carrying out pathological investigations in various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, Immunology, virology, cytology, other pathological and radiological investigations
The company's stock opened at Rs 820 on the BSE, rose by 2.3 per cent after the results were declared and closed for the day at Rs.835.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.